BREAKING: OpenAI CEO Sam Altman has revealed that his experimentation with semaglutide—before it gained widespread popularity—landed him in the hospital. Speaking on the “Conversations with Tyler” podcast, Altman shared that this GLP-1 medication, marketed as Ozempic and Wegovy, is linked to appetite suppression and weight loss.
Altman, who leads a high-pressure role at OpenAI, admitted that his busy schedule has shifted his focus away from personal health. “I now do basically nothing,” he confessed, citing junk food and a lack of exercise as part of his current lifestyle. The CEO’s comments come as he balances being a first-time father and managing a rapidly growing tech company.
During the podcast, Altman reflected on his changing health habits, stating, “When I was less busy, I was more disciplined on health-related stuff.” He noted that his recent approach to health is less stringent, resulting in unhealthy eating habits. Altman’s hospitalization from semaglutide usage remains vague, as he did not specify whether dehydration or another factor was involved.
The drug, which can dramatically affect weight management, has gained popularity among individuals looking to lose weight, even those without obesity or diabetes. Altman is not alone in his usage; high-profile individuals like Elon Musk have also publicly admitted to trying these medications for wellness. Musk remarked in 2022 that he used Wegovy to enhance his fitness.
The conversation around these medications has sparked interest as they enter mainstream discussions about weight and health. Altman’s candidness about his love for junk food resonates with Musk, who previously stated, “I’d rather eat tasty food and live a shorter life.” The two tech moguls share a penchant for fast food, with Altman admitting to craving chocolate chip cookies late at night.
As Altman continues to navigate his demanding role at OpenAI, which is currently valued at over $100 billion, his health choices are garnering public attention. He also mentioned other health-related efforts, such as taking metformin in 2023, which is associated with weight loss and aging research. His involvement with longevity-focused startups like Retro Biosciences further highlights his interest in health and wellness.
This evolving narrative about health consciousness among tech leaders raises questions about the pressures they face. As Altman put it, he feels “bullied into taking” his health more seriously again.
With discussions around semaglutide and its effects on lifestyle continuing to grow, many are watching Altman’s journey closely. Expect more updates as he balances his professional responsibilities with personal health considerations.
Stay tuned for more urgent updates on this developing story.
